"Trade Margin Rationalisation offers a middle path between price control and market freedom in pharmaceuticals." Critically examine this with reference to anti-cancer drugs.

Trade Margin Rationalisation (TMR) caps the margin added between the price at which a drug leaves the manufacturer and its MRP. It leaves the manufacturer's own price alone. In October 2026, NPPA applied a 30% cap to 137 non-scheduled anti-cancer drugs [1]. TMR is a real middle path, but its legal base is weak.

Why TMR is a middle path

• Targets the distortion, not production: firms keep their pricing freedom. Only supply-chain mark-ups are cut, which averaged about 170% on non-scheduled cancer drugs [1].
• Proven results: the 2019 pilot on 42 drugs cut MRPs of 526 brands by up to 90% [2]. The 2026 expansion cuts MRPs of 1,031 formulations and is estimated to save ₹3,502.31 crore a year [1].
• Fills the DPCO gap: ceiling prices reach only Schedule-I (NLEM) drugs, while TMR covers the non-scheduled market [1].
• Covers newer therapies: it includes immunotherapies and biologics such as Bevacizumab [7]. It also covers drugs not yet launched in India, so their launch prices cannot be set high [1].
• Protects supply: companies must keep current production and supply levels [1].

Limitations

• Weak legal base: TMR relies on extraordinary powers under Para 19 of DPCO 2013 [3]. The Standing Committee (August 2026) found no timeline for building a permanent TMR framework into DPCO [4].
• A flat 30% favours costly drugs: 30% of a ₹1-lakh biologic is ₹30,000. WHO recommends regressive mark-ups, where the allowed rate falls as the price rises [6].
• Core price untouched: for patented biologics, most of the price is the manufacturer's own price.
• Selective coverage: retail margins on anti-cancer drugs are still 50–60%. The Health Committee wants TMR on all anti-cancer molecules [5].
• Weak enforcement: about 85% of overcharging demands have not been recovered, mostly because they are stuck in litigation [4].
• Narrow relief: 70–80% of cancer treatment cost is paid out of pocket, and much of that is not medicines [5].

Way forward

• Write TMR into DPCO with a timeline, using slab-based margins.
• Set up fast-track dispute resolution and a dedicated legal cell in NPPA [4].
• Pair price caps with PM-JAY insurance and Jan Aushadhi generics.

TMR lowers inflated MRPs without fixing what manufacturers charge, so it sits between control and the free market. To last, it needs a permanent legal basis, margins that fall as prices rise, and strong recovery of overcharges. Combined with insurance, it can advance the Article 21 right to health and SDG 3.8 (universal health coverage).